Effective elimination of latently infected cells in people living with HIV (PLWH) on antiretroviral therapy (ART) through activation of HIV transcription will also require the induction of death of the infected cell. Given that HIV proteins, such as envelope and vpr, expressed late in the productive replication cycle, can induce apoptosis of CD4+ T-cells, we hypothesised that using latency reversing agents (LRAs) to induce expression of pro-apoptotic viral proteins combined with pro-apoptotic drugs will enhance the reduction of latently infected cells.
Total CD4+ T-cells were isolated from peripheral blood collected by leukapheresis from PLWH on ART. CD4+ T-cells were treated with pro-apoptotic drugs (the phoshoinositide-3 kinase (PI3K) inhibitors, IPI-443, IPI-3063 and wortmannin or an inhibitor of B-cell lymphoma (Bcl)-2, venetoclax) for 24 hours, followed by treatment with five different latency reversing agents (LRAs; panobinostat, romidepsin, bryostatin, JQ1 or PMA/PHA) for 4 or 24 hours and then the pro-apoptotic drugs alone for a further 48 hours. We measured integrated HIV DNA and cell-associated unspliced (CA-US) HIV RNA by RT-qPCR.
The combined treatment of romidepsin with each of the four pro-apoptotic drugs led to a greater decline in integrated HIV DNA versus either romidepsin or pro-apoptotic drug alone. Romidepsin together with 5nM venetoclax showed the greatest decline in integrated HIV DNA. Romidepsin or venetoclax alone resulted in a mean fold change (MFC) in HIV integrated DNA of 0.72 and 0.18, respectively while the combined treatment resulted in an MFC of 0.54. Panobinostat and JQ1 combined with 1μM venetoclax also led to a reduction in HIV integrated DNA (PNB+1μM VNX MFC=0.47; JQ1+1μM VNX MFC=0.60), compared to the decline resulting from each drug alone (PNB MFC=0.71; JQ1 MFC=0.88; 1μM VNX MFC=0.76). We observed increases in CA-US HIV RNA and the ratio of CA-US HIV RNA to integrated DNA following treatment of CD4+ T-cells with all four LRAs as well as each of the pro-apoptotic drugs alone or combined.
Using CD4+ T-cells from PLWH on ART ex vivo, reduction of integrated HIV DNA could be significantly enhanced using the combination of romidepsin with either a PI3K or Bcl-2 inhibitor. The addition of a pro-apoptotic drug could potentially provide the ‘’kill’’ needed for effective ‘’shock and kill’’.